Effect of risperidone on serum IL-6 levels in individuals with schizophrenia: a systematic review and meta-analysis.
Saved in:
| Title: | Effect of risperidone on serum IL-6 levels in individuals with schizophrenia: a systematic review and meta-analysis. |
|---|---|
| Authors: | Ramos-Méndez, Miguel Angel, Tovilla-Zárate, Carlos Alfonso, Juárez-Rojop, Isela Esther, Villar-Soto, Mario, Genis-Mendoza, Alma Delia, González-Castro, Thelma Beatriz, López-Narváez, María Lilia, Martínez-Magaña, José Jaime, Castillo-Avila, Rosa Giannina, Villar-Juárez, Guillermo Efrén |
| Source: | International Journal of Psychiatry in Clinical Practice. Jun2023, Vol. 27 Issue 2, p171-178. 8p. |
| Subjects: | Blood serum analysis, Drug therapy for schizophrenia, Interleukins, Online information services, Meta-analysis, Systematic reviews, Descriptive statistics, MEDLINE, Data analysis software, Risperidone |
| Abstract: | Risperidone has been significant correlated with a direct effect of interleukin-6 (IL-6) levels in patients with schizophrenia. This fact allows the opportunity to link the probable immunomodulatory effect of antipsychotic medication. Specially, a proper functioning of IL-6 pathway plays a potential role in the treatment or development of schizophrenia. Our primary aim was to perform a systematic review and meta-analysis to determine the effect of risperidone on IL-6 levels in individuals with schizophrenia. Studies were identified through a systematic search using PubMed, Scopus, and Web of Science databases. The articles found were subjected to the inclusion and exclusion criteria; then, the mean and standardised differences were extracted to calculate the standardised mean differences using the CMA software. IL-6 levels in individuals with schizophrenia were compared before and after receiving risperidone as treatment. Increased levels of IL-6 levels were observed in individuals with schizophrenia who received risperidone (point estimate 0.249, lower limit 0.042, upper limit 0.455, p-value 0.018). In the Asian population sub-analysis, no statistically significant differences were observed (point estimate 0.103, lower limit −0.187, upper limit 0.215, p value 0.890). When we compared individuals with schizophrenia to the control groups, a significant increase of IL-6 levels was observed in the group with schizophrenia (point estimate 0.248, lower limit 0.024, upper limit 0.472, p-value 0.30). Risperidone appears to play an important role in IL-6 levels in schizophrenia. Potential implications of increased IL-6 levels in people with schizophrenia should be considered in future studies. Increased levels of IL-6 levels were observed in individuals with schizophrenia who received risperidone. Risperidone appears to play an important role in IL-6 levels in schizophrenia. This study could serve for future research focussed on IL-6. [ABSTRACT FROM AUTHOR] |
| Copyright of International Journal of Psychiatry in Clinical Practice is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
